Ya-Nin Nokdhes

Ya-Nin Nokdhes

Auto-generated profile, based on publicly available information

Ya-Nin Nokdhes

Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkok Noi, Bangkok 10700, Thailand

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SJSukhum Jiamton
Sukhum Jiamton
PCPattriya Chanyachailert
Pattriya Chanyachailert
YNYanisorn Nanchaipruek
Yanisorn Nanchaipruek
NJNuttagarn Jantanapornchai
Nuttagarn Jantanapornchai
PPPoramin Patthamalai
Poramin Patthamalai
JJJiraporn Jantaravinid
Jiraporn Jantaravinid
Human papillomavirus (HPV) infection causes condyloma acuminata (CA). Podophyllin is the standard treatment. Clinacanthus nutans Lindau (C. nutans), a medicinal plant, has potent anti-inflammatory and antiviral effects. C. nutans cream is widely used in Thailand to treat the herpes simplex virus. We proposed that C. nutans might also induce CA clearance. There are no studies of C. nutans treatment of CA. This randomized controlled trial at Siriraj Hospital, Thailand, was conducted between January 2018 and December 2019. CA samples were obtained from 10 men with at least two CAs 1 centimeter apart. Each wart was randomized to a 4-week treatment with either C. nutans or podophyllin. The participants were 24 to 72 years old. Most HPV types were low-risk HPVs (HPV 11, HPV 6). Median CA clearance with podophyllin was a 97 CA clearance with podophyllin and 82 with C. nutans. C. nutans may be an alternative treatment for CA.

9 May 2024 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
SSSurachet Sirisuthivoranunt
Surachet Sirisuthivoranunt
SWSupisara Wongdama
Supisara Wongdama
PPPhumithep Phumariyapong
Phumithep Phumariyapong
YNYa-Nin Nokdhes
Ya-Nin Nokdhes
PTPanwadee Thongjaroensirikul
Panwadee Thongjaroensirikul
RWRungsima Wanitphakdeedecha
Rungsima Wanitphakdeedecha
Objective Botulinum toxin serotype A (BoNT/A) is widely used for minimal invasive aesthetic treatments. Different brands of BoNT/A exhibit structural variations. The aim of this study was to compare the duration and efficacy of various BoNT/A brands available in Thailand for reducing bite force and treating wrinkles. Methods Fifty participants were randomly assigned to one of five groups, with each group receiving a different BoNT/A brand, namely, incobotulinumtoxinA (IncoA), onabotulinumtoxinA (OnaA), abobotulinumtoxinA (AboA), letibotulinumtoxinA (LetiA), and prabotulinumtoxinA (PraboA). BoNT/A was administered to the masseter muscle and the upper face. Bite force was measured before injection and at 2, 4, 8, 12, 16, 20, and 24 weeks post-injection. Evaluation scores for wrinkle improvement were assessed after the treatment. Results The most significant reduction in bite force occurred between 2 and 4 weeks post-injection. PraboA demonstrated the most substantial reduction in bite force, while IncoA had the least effect. However, the percentage of bite force reduction did not exhibit statistical significance between BoNT/A types. Additionally, the reduction in bite force for all BoNT/A types was reversed at 4 months post-injection. More than half of the participants experienced improvement beyond 16 weeks. Conclusions The structural differences among BoNT/A brands did not significantly affect the longevity and efficacy of bite force reduction and wrinkle treatment. Trial Registration ClinicalTrials.gov identifier: TCTR20211205001 (registered 4 Dec 2021).

11 July 2025 in Toxins
Verified
Journal Article
Open access
PDF file
Juthapa PongklaokamJuthapa Pongklaokam
Juthapa Pongklaokam
WMWoraphong Manuskiatti
Woraphong Manuskiatti
RWRungsima Wanitphakdeedecha
Rungsima Wanitphakdeedecha
PMPitchaya Maneeprasopchoke
Pitchaya Maneeprasopchoke
PTPanwadee Thongjaroensirikul
Panwadee Thongjaroensirikul
Thanya TechapichetvanichThanya Techapichetvanich
Thanya Techapichetvanich
Background: Melasma is an acquired hyperpigmentation disorder with multifactorial etiologies and limited response to conventional therapies. Recent evidence suggests that Botulinum Toxin A (BoNT-A) may modulate ultraviolet (UV)-induced pigmentation and offer therapeutic benefits. Objective: We sought to evaluate the efficacy and safety of two intradermal dilutions of Letibotulinum toxin A (LetiBoNT-A) in Thai patients with melasma. Methods: In this randomized, double-blind, split-face study, 30 participants aged 32–62 years received a single intradermal injection of LetiBoNT-A, with 20 units administered per cheek. A 1:5 dilution was injected on one side of the face, and a 1:10 dilution was injected on the contralateral side. Outcomes were evaluated over a 6-month period using the Hemi-modified Melasma Area and Severity Index (Hemi-mMASI), VISIA® brown spot analysis, and quantitative assessments of skin texture. Results: Both dilutions significantly improved Hemi-mMASI scores (1:5, p = 0.043; 1:10, p = 0.002) and brown spots (1:5, p = 0.002; 1:10, p < 0.001). The 1:10 dilution showed earlier and more sustained improvements. Subgroup analysis revealed greater reductions in Hemi-mMASI scores among patients with telangiectatic melasma, particularly with the 1:10 dilution, though they were not statistically significant. Additionally, the 1:10 dilution significantly reduced pore volume, pore area, and sebum levels. One case of transient facial asymmetry was reported with the 1:5 dilution. Conclusions: LetiBoNT-A is a safe and effective adjunct in melasma treatment. The 1:10 dilution offered superior clinical outcomes.

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
RWRungsima Wanitphakdeedecha
Rungsima Wanitphakdeedecha
KKKatrina Kashmyr Borjal Kua-Uy
Katrina Kashmyr Borjal Kua-Uy
Chadakan YanChadakan Yan
Chadakan Yan
YNYa-Nin Nokdhes
Ya-Nin Nokdhes
PSPanittra Suphatsathienkul
Panittra Suphatsathienkul
TLThanyaporn Leesanguankul
Thanyaporn Leesanguankul
Introduction. Visibly enlarged facial pores are familiar dermatologic concerns. Macrofocused ultrasound energy without visualization (MaFU‐WV) showed efficacy in facial tightening and an improvement in skin textural irregularities which opened the potential of the positive effects in reducing the appearance of facial pores. This study aims to assess the safety and efficacy of MaFU‐WV in tightening facial pores. Methods. This was a prospective, single‐blinded pilot study. Thirty‐four Thai subjects with enlarged pores received a single treatment of MaFU‐WV using a 2.0 mm transducer on bilateral malar areas of the face. Primary outcome measures included the pore count, pore volume, and pore index measurements using an instrument with a camera for image acquisition and software for analysis of skin. Secondary outcome measures incorporated two blinded dermatologists’ evaluation of clinical photographs and the subjects’ perception of improvement in their facial pores using a 6‐point scale. Measurements were taken at baseline, 1 week, 1 month, 3 month, and 6 month after treatment. Results. The pore count significantly decreased from baseline to 6 month after treatment (p < 0.001). Pore volume was significantly lowered from baseline to 1 week and 1, 3, and 6 months after treatment (p < 0.05). The pore index was likewise significantly reduced from baseline in every visit (p < 0.05). The majority of photographic evaluations by blinded dermatologists were scored as a 1–25% pore minimizing effect across nearly all follow‐up visits. On the other hand, patient satisfaction kept improving until the end of the study at 6 months. No adverse events occurred throughout the conduct of the study. Conclusion. Macrofocused ultrasound energy using a 2 mm transducer is a safe and effective treatment for facial pore tightening. The trial is registered with registration number: TCTR20220719001.

2 February 2021 in Rural and Remote Health
Verified
Journal Article
Open access
SJSukhum Jiamton
Sukhum Jiamton
NJNuttagarn Jantanapornchai
Nuttagarn Jantanapornchai
YNYa-Nin Nokdhes
Ya-Nin Nokdhes
PPPoramin Patthamalai
Poramin Patthamalai
PTPloypailin Tantrapornpong
Ploypailin Tantrapornpong
OPOraya Pochanapan
Oraya Pochanapan
RRH: Rural and Remote Health. Published article number: 6378 - Clinical manifestations and progression, seasonal variation, and environmental factors associated with Paederus dermatitis among patients attending the outpatient dermatology clinic of Thailand’s largest national tertiary referral center: a prospective cohort study

17 November 2026 in Life
Verified
Journal Article
Open access
PDF file
SSSirapob Seksunwiriya
Sirapob Seksunwiriya
SWSoponvit Wattanakul
Soponvit Wattanakul
Thanya TechapichetvanichThanya Techapichetvanich
Thanya Techapichetvanich
PMPitchaya Maneeprasopchoke
Pitchaya Maneeprasopchoke
PTPanwadee Thongjaroensirikul
Panwadee Thongjaroensirikul
RWRungsima Wanitphakdeedecha
Rungsima Wanitphakdeedecha
Background: Melasma is a chronic relapsing pigmentary disorder in which ultraviolet and visible-light exposure may contribute to melanogenic signaling partly through oxidative stress. Objective: To describe exploratory clinical and tolerability observations during use of an HPR/retinol-based serum with tinted sunscreen containing Polypodium leucotomos extract. Methods: Thirty adults with melasma and Fitzpatrick skin types III–IV entered this single-arm prospective study. Serum was used nightly for 8 weeks and sunscreen daily for 12 weeks. Primary outcomes in the pre-enrollment protocol were Antera3D pigmentation and Mexameter melanin and erythema indices; physician-assessed severity and biophysical measures were secondary. Registration occurred after study completion. Results: Twenty-seven participants completed follow-up. At month 3, reported mean Antera3D pigmentation decreased from 46.63 to 44.57, Mexameter melanin index from 262.90 to 224.60, and mMASI from 7.80 to 6.32, corresponding to descriptive reductions of 4.4%, 14.6%, and 19.0% in the respective group means. Reported p values were exploratory. Increased Cutometer R0 indicated greater deformation under suction and did not establish improved firmness or elasticity. Ten participants reported local irritation; no moderate or severe adverse events or adverse-event-related discontinuations were reported. Conclusion: Modest within-cohort changes were observed. The uncontrolled concurrent-intervention design cannot establish efficacy, comparative effectiveness, synergy, or the contribution of either product or individual ingredient. These observations are hypothesis-generating; antioxidant-mediated efficacy cannot be inferred.